Is Bioventus Inc. overvalued?

Bioventus Inc. (BVS) looks undervalued — trading about 82% below its fair value.

Undervalued

Price

$14.02

Fair value

$25.51

Current P/E

18.7

Normal P/E

34.0

Market cap

$949.8M

Dividend yield

0.0%

Return on equity

28.4%

Sector

Healthcare

Fair value compares BVS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks